
==== Front
Eur Radiol
Eur Radiol
European Radiology
0938-7994
1432-1084
Springer Berlin Heidelberg Berlin/Heidelberg

38656709
10770
10.1007/s00330-024-10770-z
Invited Review
Biparametric MRI in prostate cancer during active surveillance: is it safe?
Caglic Iztok 1
Sushentsev Nikita 12
Syer Tom 12
Lee Kang-Lung 234
http://orcid.org/0000-0002-1180-1474
Barrett Tristan tb507@medschl.cam.ac.uk

12
1 grid.120073.7 0000 0004 0622 5016 Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, United Kingdom
2 https://ror.org/013meh722 grid.5335.0 0000 0001 2188 5934 Department of Radiology, University of Cambridge, Cambridge, United Kingdom
3 https://ror.org/03ymy8z76 grid.278247.c 0000 0004 0604 5314 Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan
4 https://ror.org/00se2k293 grid.260539.b 0000 0001 2059 7017 School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
24 4 2024
24 4 2024
2024
34 10 62176226
2 2 2024
13 3 2024
22 3 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Abstract

Active surveillance (AS) is the preferred option for patients presenting with low-intermediate-risk prostate cancer. MRI now plays a crucial role for baseline assessment and ongoing monitoring of AS. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations aid radiological assessment of progression; however, current guidelines do not advise on MRI protocols nor on frequency. Biparametric (bp) imaging without contrast administration offers advantages such as reduced costs and increased throughput, with similar outcomes to multiparametric (mp) MRI shown in the biopsy naïve setting. In AS follow-up, the paradigm shifts from MRI lesion detection to assessment of progression, and patients have the further safety net of continuing clinical surveillance. As such, bpMRI may be appropriate in clinically stable patients on routine AS follow-up pathways; however, there is currently limited published evidence for this approach. It should be noted that mpMRI may be mandated in certain patients and potentially offers additional advantages, including improving image quality, new lesion detection, and staging accuracy. Recently developed AI solutions have enabled higher quality and faster scanning protocols, which may help mitigate against disadvantages of bpMRI. In this article, we explore the current role of MRI in AS and address the need for contrast-enhanced sequences.

Clinical relevance statement

Active surveillance is the preferred plan for patients with lower-risk prostate cancer, and MRI plays a crucial role in patient selection and monitoring; however, current guidelines do not currently recommend how or when to perform MRI in follow-up.

Key Points

Noncontrast biparametric MRI has reduced costs and increased throughput and may be appropriate for monitoring stable patients.

Multiparametric MRI may be mandated in certain patients, and contrast potentially offers additional advantages.

AI solutions enable higher quality, faster scanning protocols, and could mitigate the disadvantages of biparametric imaging.

Keywords

Prostate cancer
MRI
Active surveillance
Biparametric
issue-copyright-statement© European Society of Radiology 2024
==== Body
pmcIntroduction

Active surveillance (AS) is a strategy recommended by the European Association of Urology (EAU) for patients presenting with low or favourable intermediate-risk prostate cancer (PCa) [1]. AS involves identifying optimal timings for curative treatments based on individual cancer grade, stage, and patient preference to safely delay or avoid radical treatments along with their potential side effects whilst maintaining oncological outcomes. The overall safety of AS in patients with clinically localised PCa has been established through several randomised controlled trials, such as ProtecT and PIVOT [2, 3], which relied on systematic biopsies as means of patient risk stratification. Disease-specific mortality in both trials remained very low despite the potential for understaging and undergrading in the pre-MRI era; hence, the argument for AS in low- and intermediate-risk disease is strong [4].

AS is implemented through regular monitoring of prostate-specific antigen (PSA), along with repeated MRI examinations and protocol-driven repeat biopsies. Eligibility criteria for AS vary across international, national, and local guidelines. These criteria are primarily based on factors such as Gleason score, cancer biopsy core volume, PSA levels, and clinical stage. Typically, AS is recommended for Gleason grades ≤ 3 + 3, PSA ≤ 10 ng/mL, and T-stage ≤ 2a, with some guidelines further supporting its use for favourable intermediate-risk Gleason 3 + 4 disease [1, 5, 6].

MRI is now considered a crucial baseline assessment for AS eligibility and for ongoing monitoring [7]. Baseline MRI aids in lesion detection and targeted biopsy, improving initial risk classification and reducing the likelihood of under-sampling compared to non-targeted biopsy approaches [8]. A negative MRI is more likely to indicate lower-grade pathology better suited for AS [9]. Conversely, the presence of a PI-RADS score of 4 or 5 lesion predicts higher-grade disease, which may render patients ineligible for AS [10]. Local staging with MRI to confirm organ-confined disease is also important for AS eligibility. Meta-analyses of MRI in AS follow-up report a high pooled NPV ranging from 0.81 to 0.88, and lower PPV ranging from 0.37 to 0.50, which may be due to several factors, including variability in measurements, subjective assessment of lesion conspicuity and lack of quantitative thresholds [11, 12]. The relatively low PPV for identifying disease progression poses a risk of over-treatment, thus MRI progression alone should not be the only trigger for repeat biopsy or even treatment. Instead, it should be considered among other clinical factors in a decision-making process, such as dynamic changes of PSA and PSA density [7, 13]. In this article we explore the current role of MRI in AS and how this should be performed, in particular addressing the need for contrast-enhanced sequences.

Mutiparametric versus Biparametric MRI

Currently, PI-RADS v2.1 guidelines recommend a full multiparametric MRI (mpMRI) protocol, including T2-weighted (T2W), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) sequences for patients presenting with suspected localised or locally advanced prostate cancer [14]. The risks linked to Gadolinium-based contrast agents usage include allergic reactions, with severe adverse reactions occurring in only 0.005% [15]. Gadolinium has also been shown to deposit in a dose-dependent manner within the globus pallidus and the dentate nucleus and has been implicated in causing nephrogenic systemic fibrosis (NSF) in individuals with renal failure [16–20]. Biparametric MRI (bpMRI) comprising T2- and diffusion-weighted sequence without contrast administration presents several potential advantages to mpMRI, including cost savings, greater flexibility in scanning patients out-of-hours, and eliminating potential for side effects of contrast agents [21–24].

In the initial diagnostic setting, a biparametric approach may be preferred if high-quality imaging and expert interpretation are available, alongside the potential for patient recall or on-table monitoring [23, 25]. In 2018, 34.9% of centres in the UK performed bpMRI as a default protocol in biopsy-naïve patients [26]. This practice is supported by a systematic review of 6055 patients in 44 studies showing equivalent performance for bpMRI and mpMRI, with a slight increase in sensitivity of 0.87 versus 0.84 for mpMRI offset by a reduced specificity of 0.72 compared to 0.75 for bpMRI [27]. However, it should be noted that the included studies were exclusively retrospective or single-centre prospective studies, with heterogeneous inclusion criteria, and where mpMRI ultimately dictated the biopsy decision [28]. Furthermore, a randomised controlled trial of 311 biopsy-naïve patients showed a 9.2% higher detection of clinically significant PCa (csPCa) for mpMRI, although this did not reach significance, the study may have been underpowered [29]. Prospective head-to-head studies are currently recruiting to further address this issue [30, 31].

The PRECISE role of MRI in AS

During the monitoring phase of AS, EAU guidelines recommend the use of MRI in men with rising PSA [1]. However, the frequency and intensity of MRI follow-up are not defined yet. This may be performed at routine, pre-determined time points [32], or may be triggered by PSA kinetics or clinical signs of progression. In addition, some centres have advocated their own institutional risk-based tailored approach, which could inform more personalised AS strategies [33, 34]. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations provide a standardised tool and scoring system for assessing the likelihood of radiological progression on MRI during AS [35]. The PRECISE system assigns 5 categories of stability or change in MRI, with score 3 representing radiological stability, scores 1–2 reduction of previously suspicious MRI features, and PRECISE 4–5 progressive disease, which typically triggers a repeat biopsy (Table 1). Imaging signs of progression include increased conspicuity, increase in PI-RADS score, appearance of new lesions, increased lesion size, or worsening disease stage. Notably, the role of DCE is not explicitly discussed, unlike with T2W and DWI which are the dominant sequences and from which lesion size, a key metric, is obtained. However, the parameter of conspicuity inherently relates also to DCE and should be evaluated in relation to the background of the gland. This becomes especially apparent in patients with prostatitis, as the diffuse changes observed on mpMRI (particularly on T2W and DCE) can pose challenges in delineating the exact extent of the lesion. However, the recommendations acknowledge the absence of robust data on which to base a threshold for a significant change in size or conspicuity. A recent single study by Sushentsev et al recommended a 20% increase in the size on T2W and/or a 10% decrease in apparent diffusion coefficient (ADC) values; however, the study did further focus on DCE. Despite certain limitations of the PRECISE assessment system [36], a systematic review has shown a trend towards improved performance over institute-specific systems, likely due to the more objective categorisation of potential progression [11].Table 1 PRECISE guidelines MRI assessment of radiological progression in AS follow-up

PRECISE category	Radiological features	
1	Resolution of previous features suspicious on MRI	
2	Reduction in volume and/or conspicuity of previous features suspicious on MRI	
3	Stable MRI appearance: no new focal/diffuse lesions	
4	Significant increase in size and/or conspicuity of features suspicious for prostate cancer	
5	Definitive radiologic stage progression	
Adapted from reference [35]

Biparametric MRI in AS

The PRECISE guidelines were formed through a multidisciplinary consensus approach, and state that MRI protocols should meet the minimum criteria set by PI-RADS, but do not explicitly outline whether MRI should be performed with or without contrast administration. Sushentsev et al reported a 9.6-fold increase in the number of AS scans performed between 2010 and 2018 [37], consistent with trends in other tertiary referral centres in the US and Europe [38, 39], making shortened-protocols attractive for adequately managing the ever-growing demand on imaging services. Abbreviated protocols, which limit sequences to the axial plane can further reduce scan time and aid patient throughput [34]; Table 2. Such approaches have the added advantages of lower costs, reduced risk of gadolinium deposition and/or contrast reactions and may be better tolerated by patients.

The role of MRI in AS follow-up is substantially different from the initial diagnostic MRI. Patients have already been characterised with MRI, have a biopsy-proven diagnosis of lower-risk disease, and the paradigm is to assess for “radiologically significant” progression, defined as a PRECISE score 4–5 [35]. Aside from further MR imaging, patients will also have the clinical safety net of continuing outpatient clinic appointments, with regular PSA checks and protocol-driven repeat biopsies. Indeed, a recent PI-RADS committee narrative review suggested bpMRI as an option in patients undergoing routine AS follow-up [23]. However, contrast is mandated for patients at higher risk of progression due to fast PSA doubling times or changing clinical or pathologic status, wherein the balance between under-diagnosis and over-diagnosis leans toward the clinical priority of not missing significant cancer [23]. It would also be reasonable to perform mpMRI following interventions that alter the background signal or morphology of the gland, including transurethral resection of the prostate (TURP), holmium laser enucleation of the prostate (HoLEP), embolisation, finasteride, or radiotherapy for other pelvic malignancy (Table 3).

To date, there have been few studies assessing the added value of contrast-enhanced MRI over a biparametric approach in patients on AS; however, a prospective trial is currently recruiting [40]. Kortenbach et al showed that pre-biopsy bpMRI improved AS selection as compared to systematic TRUS biopsy [41], with the same group also demonstrating that bpMRI was non-inferior to mpMRI for AS enrolment based on early repeat imaging and biopsy [42]. Of the six studies reporting outcomes using the PRECISE scoring system, only one did not routinely use contrast for follow-up imaging [43], and none of the studies reported the individual MRI components contributing to the overall PRECISE score, thereby limiting the evaluation of the specific role of DCE during follow-up [11].

Two recent meta-analyses on MRI and PRECISE scoring during AS have been conducted, with 1 out of 15 and 0 out of 7 studies using bpMRI, respectively [11, 12]. The single study reporting on a bpMRI approach used mpMRI at baseline and an abbreviated 20-minute bpMRI protocol in follow-up. Despite this approach, the results are encouraging, with a higher NPV (0.96) than the pooled NPV (0.81–0.88), even with a long median follow-up of 52 months. Additionally, the study included patients with GG2 cancers, unlike the majority of other studies that included only men with GG1 disease. The PPV was also higher at 0.52, compared to the overall pooled PPV of 0.37–0.50 [40]. It is important to note that the study was conducted in a tertiary centre with expert prostate reporters and may not be transferrable to other settings. This caution aligns with findings from pre-biopsy MRI studies, indicating significantly worse diagnostic performance and confidence for less experienced readers when using bpMRI for lesion detection compared to mpMRI [44–46].

The NPV should be maximised in AS patients when the risk of treatment still overall outweighs the benefit of oncological control, and the prospect of repeated biopsies is the main reason for discontinuing AS by patients [7, 47–49]. The similar NPV of bpMRI compared to mpMRI suggests their equivalent potential for safely reducing the number of unnecessary biopsies and increasing patient adherence to AS protocols. The higher specificity of bpMRI compared to mpMRI for the detection of csPCa [27] may therefore be beneficial [11] and draws parallels with MRI-based prostate cancer screening, where a biparametric approach is advocated to help maximise specificity over sensitivity for the detection of significant cancer [50]. Notably, one of the main limitations of DCE is its relative non-specificity. In addition to tumours, both prostatitis and highly vascularised benign prostatic hyperplasia (BPH) nodules can result in rapid enhancement and wash-out, and false-positive results can also arise secondary to peri-lesional inflammatory change (Fig. 1). It is therefore essential to interpret DCE MRI results in combination with T2W and DWI sequences.

The current PRECISE system does not specifically define the appearance of new lesions [44–46]. Available studies typically categorised these as PRECISE 4 [36]. Notably, the PPV of MRI for predicting progression for new lesions was observed to be significantly lower at 24% compared to PRECISE scores 4–5 for pre-existing lesions (63%) in a recent study including 295 men [43]. Similarly, a study by Ghavimi et al showed that the majority of new lesions on follow-up scans were not of clinical significance and did not alter patient management [51]. A risk-tailored approach using bpMRI may therefore decrease the proportion of new PI-RADS 4 lesions, sparing men with low PSA-D from serial unnecessary biopsies [13].

There are also potential disadvantages of a biparametric approach (Table 4). DCE can act as a “safety net” sequence for image quality [52], and in the context of poor-quality imaging, PRECISE scoring cannot adequately be applied [36]; Fig. 2. DCE may also aid new lesion detection, particularly for lesion experienced readers [53], and may have advantages for accurate staging of the gland, particularly seminal vesicle invasion [54]. As expected, given the dominant and secondary sequence paradigm of PI-RADS, bpMRI will increase the number of indeterminate score 3 lesions in the PZ by 6.9–8.9% [46, 55, 56]. A baseline PI-RADS 4 lesion, up-scored by DCE (i.e. “3 + 1”) will be categorised as PI-RADS 3 on bpMRI follow-up assuming no change (Fig. 3). Theoretically, this change in PI-RADS score would be assigned as PRECISE category 2 due to a “reduction in the conspicuity of previous features suspicious on MRI”, despite the stability of the lesion itself. In practice, readers are likely to compare the biparametric alone sequences and assign a PRECISE score 3; again, such cases may help improve PPV by reducing the proportion of lesions scoring PI-RADS 4. Another consideration is the unknown effect on inter-reader agreement for PRECISE scoring at bpMRI, which to date has only been assessed using mpMRI, with Giganti et al reporting excellent agreement between two expert readers using mpMRI during AS [57].Table 2 Local multiparametric, biparametric and abbreviated MRI protocols

Protocol	Localisers	Axial T1 FSE	Axial T2 FSE	Sagittal T2 FSE	Axial DWI large FOV	Axial DWI small FOV	DCE	Total time	
Multiparametric	00:35	02:32	05:22	03:13	02:42	04:52	06:22	25:59	
Biparametric	00:35	02:32	05:22	03:13	02:42	04:52	X	19:37	
Abbreviated (AS)	00:56	02:32	05:22	X	02:42	X	X	11:32	
FOV field-of-view, FSE fast spine echo

Table 3 Scenarios where an mpMRI approach is favoured in patients on AS

Scenarios where mpMRI approach is recommended	
Patients at higher risk of progression (e.g. fast PSA doubling time, changing clinical or pathological status)	
Pelvic metalwork (e.g. THR, surgical clips)	
Prior prostate interventions (e.g. TURP, HoLEP, embolisation, finasteride, pelvic radiotherapy)	
Patient-related factors affecting image quality (e.g. motion, rectal distension, high BMI)	
BMI body mass index, THR total hip replacement

Fig. 1 False positive DCE findings on AS follow-up. 74-year-old patient, presenting PSA 10.95 ng/mL. A–C Baseline MRI shows ill-defined T2 change (A) at the left mid-PZ, with a 12 × 9 mm area of marked restricted diffusion (B), with associated focal early enhancement (C), consistent with a PI-RADS 4 lesion (arrows). Targeted biopsy shows Gleason 3 + 4 = 7 (10% Gleason 4) in 3/3 cores. D–F MRI at 12 months, PSA 10.84 ng/mL. Stable conspicuity and size of lesion on T2 (D) and ADC maps (E), but increase in the degree of enhancement to 22 × 12 mm (F, arrows). PRECISE score 3—findings considered a false positive. The patient remains on AS

Table 4 Advantages and disadvantages of bpMRI in patients on AS

	Advantages	Disadvantages	
General	• Avoids adverse Gadolinium reactions

• Perform outside core hours

• Reduced need for medical back-up

• Cost savings

	• Increase in number of nondiagnostic studies

• Higher indeterminate PI-RADS 3 calls rate

• Impact on reading and confidence of less experienced radiologists

• DCE may improve T-staging accuracy

	
During Follow-up	• Higher specificity for csPCa may improve PPV of radiological progression

• Abbreviated examination times and no cannula placement better tolerated by patients for multiple repeat studies

• Increased capacity and patient throughput

• Avoidance of false positive inflammatory change and downgrading lesions to PI-RADS 3 may improve PPV of radiological progression

	• Direct comparison not possible for baseline DCE positive PZ lesions (PI-RADS score “3 + 1”)

• No “safety net” in cases with reduced imaged quality may mean PRECISE scoring cannot be applied

• DCE may aid new lesion detection

• Unknown effect of omitting contrast on inter-reader agreement for PRECISE scoring

	

Fig. 2 Value of DCE in patients with poor quality DWI. 71-year-old patient with a left THR, presenting PSA 6.01 ng/mL. A–C Baseline MRI: 14 × 5 mm PI-RADS 4 lesion in the medial left apex PZ with focal low T2 signal (A), nondiagnostic DWI due to THR (B), and focal early enhancement on DCE (C). Targeted biopsy shows Gleason score 3 + 4 = 7 (approximately 5% pattern 4), in 2/2 cores, 5 mm maximum tumour length. D–F MRI at 36 months with PSA 8.63 ng/mL. Increase in conspicuity on T2 (D), DWI remains nondiagnostic (E), but with a clear increase in the degree of enhancement on DCE to 21 × 7 mm (F, arrows). PRECISE score 4. Repeat biopsy shows Gleason score 3 + 4 = 7 (40% pattern 4), in 2/2 cores, 8 mm max tumour length. The patient treated with external beam radiotherapy

Fig. 3 bpMRI versus mpMRI affecting PI-RADS score. 66-year-old patient, presenting PSA 5.88 ng/mL. A–C Baseline MRI shows ill-defined PI-RADS 3 change on T2 (A), with mild restricted diffusion on ADC (B) and b-value imaging (not shown), PI-RADS 3, with associated marked focal early enhancement, DCE positive (C, arrow). Overall PI-RADS score 3 + 1 = 4; targeted biopsy shows Gleason 3 + 4 = 7 (Pattern 4 = < 5%) extending for a maximum length of 4.2 mm. D, E MRI at 12 months, PSA 5.43 ng/mL. Stable appearances on Ts (D) and ADC maps (E, arrow); however, PI-RADS score 3, reduced from score 4 due to employment of a bpMRI only

Future directions

Artificial intelligence (AI) techniques are being routinely used in clinical settings as post-processing tools to reduce image noise using deep learning-based reconstruction (DLR) algorithms [58]. This offers the ability to further reduce scan time and/or to mitigate against the effects of poor image quality if a biparametric MRI approach is used (Fig. 4). The current version of Prostate Imaging Quality (PI-QUAL) does not allow for evaluating bp-MR image quality and PRECISE does not discuss the assessment of an AS follow-up MRI that is below acceptable quality thresholds [35, 59, 60]—both issues are likely to be addressed in subsequent versions of the guidelines scheduled for release in 2024 [61].

Recent studies pioneering the development of AI-assisted solutions for improving the baseline prediction and follow-up assessment of the risk of tumour progression on AS have to date, all used bpMRI approaches [62–65]. Importantly, two of these studies have shown comparable performance of fully quantitative AI models to expert-derived subjective PRECISE assessment, which has the potential for levelling up the performance of less experienced readers [63, 64]. Moreover, the combined predictive model using longitudinal bpMRI data together with serial PSA density has shown considerably higher performance compared to that of serial MRI results pooled across various centres [64, 66]. Furthermore, AI-assisted bpMRI assessment tools have the potential to provide automated readouts of measurable tumour characteristics, such as maximum diameter or volume [67, 68], which moving forward could help to make PRECISE-based image interpretation more objective [36].Fig. 4 Faster acquisition by applying DLR. A Standard-of-care axial fast-recovery fast-spin-echo T2WI sequence, acquisition time 4:34 minutes. B C T2 acquisition with a reduced number of and retrospectively reconstructed with medium DLR (B) and high DLR (C), with resultant reduction in scan times to 3:05 minutes and 2:19 minutes, respectively, without compromising image quality

Summary

MRI has become an established tool for monitoring disease in patients on AS. Increased demand on imaging services makes the use of shortened MRI protocols attractive to aid patient throughput. Biparametric MRI enables this and has the added benefits of avoiding Gadolinium-associated side effects and is typically better tolerated by patients.

Data from studies involving biopsy-naïve patients suggests equivalent performance between bpMRI and mpMRI; however, the results of prospective studies in this cohort, including the PRIME and PACIFIC trials, are still awaited. The approach of bpMRI in the context of AS follow-up is arguably lower risk with the paradigm-shifting from that of lesion detection to the assessment of progression, and this is further supplemented by the safety net of ongoing clinical assessment. Indeed, a PI-RADS committee narrative review implies that bpMRI is a safe option in stable patients undergoing routine AS follow-up. The improved specificity afforded by bpMRI approaches could theoretically improve the PPV of MRI and safely reduce the need for repeat biopsies, where overall disease-specific mortality is known to remain very low. However, the use of contrast can afford advantages such as greater image quality, increased staging accuracy, and improved detection of new lesions.

In conclusion, retrospective single-centre studies and data derived from biopsy-naïve patient populations implies bpMRI to be a reasonable approach in AS follow-up, provided quality-control measures are met. The technique offers several benefits, and the recent development of AI solutions may help mitigate any potential disadvantages. However, further prospective data is required to fully establish the safety and efficacy of a bpMRI approach.

Abbreviations

AS Active surveillance

bp Biparametric

mp Multiparametric

PRECISE Prostate Cancer Radiological Estimation of Change in Sequential Evaluation

PSA Prostate-specific antigen

Acknowledgements

This research was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors also acknowledge support from Cancer Research UK (Cambridge Imaging Centre grant number C197/A16465), the Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, and the Cambridge Experimental Cancer Medicine Centre.

Funding

The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Tristan Barrett.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was not required.

Ethical approval

Institutional Review Board approval was not required.

Study subjects or cohorts overlap

Not applicable.

Methodology

Review

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mottet N van den Bergh RCN Briers E EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with urative intent Eur Urol 2021 79 243 262 33172724
Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with urative intent. Eur Urol 79:243–26233172724
2. Wilt TJ Jones KM Barry MJ Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017 377 132 142 28700844
Wilt TJ, Jones KM, Barry MJ et al (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377:132–14228700844
3. Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388:1547–1558
4. Rajwa P Sprenkle PC Leapman MS When and how should active surveillance for prostate cancer be de-escalated? Eur Urol Focus 2021 7 297 300 32019719
Rajwa P, Sprenkle PC, Leapman MS (2021) When and how should active surveillance for prostate cancer be de-escalated? Eur Urol Focus 7:297–30032019719
5. Prostate cancer diagnosis and management: NICE guideline (NG131). 2019
6. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. 2022
7. Moore CM King LE Withington J Best current practice and research priorities in active surveillance for prostate cancer-a report of a Movember International Consensus Meeting Eur Urol Oncol 2023 6 160 182 36710133
Moore CM, King LE, Withington J et al (2023) Best current practice and research priorities in active surveillance for prostate cancer-a report of a Movember International Consensus Meeting. Eur Urol Oncol 6:160–18236710133
8. Klotz L Pond G Loblaw A Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up Eur Urol 2020 77 311 317 31708295
Klotz L, Pond G, Loblaw A et al (2020) Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol 77:311–31731708295
9. Gallagher KM Christopher E Cameron AJ Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies BJU Int 2019 123 429 438 30113755
Gallagher KM, Christopher E, Cameron AJ et al (2019) Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. BJU Int 123:429–43830113755
10. Westphalen AC McCulloch CE Anaokar JM Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel Radiology 2020 296 76 84 32315265
Westphalen AC, McCulloch CE, Anaokar JM et al (2020) Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 296:76–8432315265
11. Rajwa P Pradere B Quhal F Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis Eur Urol 2021 80 549 563 34020828
Rajwa P, Pradere B, Quhal F et al (2021) Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur Urol 80:549–56334020828
12. Hettiarachchi D Geraghty R Rice P Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?-A systematic diagnostic test accuracy review Eur Urol Oncol 2021 4 426 436 32972894
Hettiarachchi D, Geraghty R, Rice P et al (2021) Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?-A systematic diagnostic test accuracy review. Eur Urol Oncol 4:426–43632972894
13. Sushentsev N Abrego L Colarieti A Using a recurrent neural network to inform the use of prostate-specific antigen (PSA) and PSA density for dynamic monitoring of the risk of prostate cancer progression on active surveillance Eur Urol Open Sci 2023 52 36 39 37182116
Sushentsev N, Abrego L, Colarieti A et al (2023) Using a recurrent neural network to inform the use of prostate-specific antigen (PSA) and PSA density for dynamic monitoring of the risk of prostate cancer progression on active surveillance. Eur Urol Open Sci 52:36–3937182116
14. Turkbey B Rosenkrantz AB Haider MA Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 2019 76 340 351 30898406
Turkbey B, Rosenkrantz AB, Haider MA et al(2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–35130898406
15. McDonald JS Hunt CH Kolbe AB Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281 945 injections Radiology 2019 292 620 627 31264948
McDonald JS, Hunt CH, Kolbe AB et al (2019) Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281 945 injections. Radiology 292:620–62731264948
16. McDonald RJ McDonald JS Kallmes DF Intracranial gadolinium deposition after contrast-enhanced MR imaging Radiology 2015 275 772 782 25742194
McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–78225742194
17. Kanda T Fukusato T Matsuda M Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy Radiology 2015 276 228 232 25942417
Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–23225942417
18. Gulani V Calamante F Shellock FG Kanal E Reeder SB Gadolinium deposition in the brain: summary of evidence and recommendations Lancet Neurol 2017 16 564 570 28653648
Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB (2017) Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 16:564–57028653648
19. Murata N Gonzalez-Cuyar LF Murata K Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function Invest Radiol 2016 51 447 453 26863577
Murata N, Gonzalez-Cuyar LF, Murata K et al (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51:447–45326863577
20. Ponrartana S Moore MM Chan SS Victoria T Dillman JR Chavhan GB Safety issues related to intravenous contrast agent use in magnetic resonance imaging Pediatr Radiol 2021 51 736 747 33871726
Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB (2021) Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 51:736–74733871726
21. Asbach P Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned Eur Radiol 2023 33 8413 8414 37420101
Asbach P (2023) Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned. Eur Radiol 33:8413–841437420101
22. Rouvière O Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)! Eur Radiol 2023 33 8415 8416 37436510
Rouvière O (2023) Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)! Eur Radiol 33:8415–841637436510
23. Schoots IG Barentsz JO Bittencourt LK PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review AJR Am J Roentgenol 2020 216 3 19 32812795
Schoots IG, Barentsz JO, Bittencourt LK et al (2020) PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216:3–1932812795
24. Porter KK King A Galgano SJ Sherrer RL Gordetsky JB Rais-Bahrami S Financial implications of biparametric prostate MRI Prostate Cancer Prostatic Dis 2020 23 88 93 31239513
Porter KK, King A, Galgano SJ, Sherrer RL, Gordetsky JB, Rais-Bahrami S (2020) Financial implications of biparametric prostate MRI. Prostate Cancer Prostatic Dis 23:88–9331239513
25. Barrett T Ghafoor S Gupta RT Prostate MRI qualification: AJR expert panel narrative review AJR Am J Roentgenol 2022 219 691 702 35544372
Barrett T, Ghafoor S, Gupta RT et al (2022) Prostate MRI qualification: AJR expert panel narrative review. AJR Am J Roentgenol 219:691–70235544372
26. Davies C Castle JT Stalbow K Haslam PJ Prostate mpMRI in the UK: the state of the nation Clin Radiol 2019 74 894.e11 894.e18 31627803
Davies C, Castle JT, Stalbow K, Haslam PJ (2019) Prostate mpMRI in the UK: the state of the nation. Clin Radiol 74:894.e11–894.e1831627803
27. Bass EJ Pantovic A Connor M A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk Prostate Cancer Prostatic Dis 2021 24 596 611 33219368
Bass EJ, Pantovic A, Connor M et al (2021) A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis 24:596–61133219368
28. Belue MJ Yilmaz EC Daryanani A Turkbey B Current status of biparametric MRI in prostate cancer diagnosis: literature analysis Life (Basel) 2022 12 804 35743835
Belue MJ, Yilmaz EC, Daryanani A, Turkbey B (2022) Current status of biparametric MRI in prostate cancer diagnosis: literature analysis. Life (Basel) 12:80435743835
29. Russo F Mazzetti S Regge D Diagnostic accuracy of single-plane biparametric and multiparametric magnetic resonance imaging in prostate cancer: a randomized noninferiority trial in biopsy-naïve men Eur Urol Oncol 2021 4 855 862 33893066
Russo F, Mazzetti S, Regge D et al (2021) Diagnostic accuracy of single-plane biparametric and multiparametric magnetic resonance imaging in prostate cancer: a randomized noninferiority trial in biopsy-naïve men. Eur Urol Oncol 4:855–86233893066
30. Asif A Nathan A Ng A Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol BMJ Open 2023 13 e070280 37019486
Asif A, Nathan A, Ng A et al (2023) Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol. BMJ Open 13:e07028037019486
31. Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer (IP7-PACIFIC). 2022. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05574647
32. Thurtle D Barrett T Thankappan-Nair V Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer BJU Int 2018 122 59 65 29438586
Thurtle D, Barrett T, Thankappan-Nair V et al (2018) Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int 122:59–6529438586
33. Stavrinides V Giganti F Trock B Five-ryear outcomes of magnetic resonance imaging-based Active Surveillance for prostate cancer: large cohort study Eur Urol 2020 78 443 451 32360049
Stavrinides V, Giganti F, Trock B et al (2020) Five-ryear outcomes of magnetic resonance imaging-based Active Surveillance for prostate cancer: large cohort study. Eur Urol 78:443–45132360049
34. Light A Lophatananon A Keates A Development and external validation of the STRATified CANcer surveillance (STRATCANS) multivariable model for predicting progression in men with newly diagnosed prostate cancer starting active surveillance J Clin Med 2022 12 216 36615017
Light A, Lophatananon A, Keates A et al (2022) Development and external validation of the STRATified CANcer surveillance (STRATCANS) multivariable model for predicting progression in men with newly diagnosed prostate cancer starting active surveillance. J Clin Med 12:21636615017
35. Moore CM Giganti F Albertsen P Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a European School of Oncology Task Force Eur Urol 2017 71 648 655 27349615
Moore CM, Giganti F, Albertsen P et al (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a European School of Oncology Task Force. Eur Urol 71:648–65527349615
36. Sanmugalingam N Sushentsev N Lee KL The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review AJR Am J Roentgenol 2023 221 649 660 37341180
Sanmugalingam N, Sushentsev N, Lee KL et al (2023) The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review. AJR Am J Roentgenol 221:649–66037341180
37. Sushentsev N Caglic I Sala E The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload Br J Radiol 2020 93 20190929 31971823
Sushentsev N, Caglic I, Sala E et al (2020) The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload. Br J Radiol 93:2019092931971823
38. Cooperberg MR Meeks W Fang R Gaylis FD Catalona WJ Makarov DV Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US JAMA Netw Open 2023 6 E231439 36862409
Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV (2023) Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Netw Open 6:E23143936862409
39. de Vos II, Luiting HB, Roobol MJ (2023) Active Surveillance for Prostate Cancer: Past, Current, and Future Trends. J Pers Med 13:629
40. Biparametric vs multiparametric MRI in men on active surveillance for prostate cancer: a preliminary collaboration between the UK and France Part of the Cities partnership Programme
41. Kortenbach KC Boesen L Løgager V Thomsen HS For men enrolled in active surveillance, pre-biopsy biparametric magnetic resonance imaging significantly reduces the risk of reclassification and disease progression after 1 year Scand J Urol 2021 55 215 220 33749511
Kortenbach KC, Boesen L, Løgager V, Thomsen HS (2021) For men enrolled in active surveillance, pre-biopsy biparametric magnetic resonance imaging significantly reduces the risk of reclassification and disease progression after 1 year. Scand J Urol 55:215–22033749511
42. Thestrup KCD Løgager V Boesen L Thomsen HS Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance Acta Radiol Open 2019 8 2058460119866352 31392035
Thestrup KCD, Løgager V, Boesen L, Thomsen HS (2019) Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance. Acta Radiol Open 8:205846011986635231392035
43. Caglic I Sushentsev N Gnanapragasam VJ MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance Eur Radiol 2021 31 2696 2705 33196886
Caglic I, Sushentsev N, Gnanapragasam VJ et al (2021) MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 31:2696–270533196886
44. Gatti M Faletti R Calleris G Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI) Abdom Radiol (NY) 2019 44 1883 1893 30788558
Gatti M, Faletti R, Calleris G et al (2019) Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol (NY) 44:1883–189330788558
45. Di Campli E Delli Pizzi A Seccia B Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience Eur J Radiol 2018 101 17 23 29571792
Di Campli E, Delli Pizzi A, Seccia B et al (2018) Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience. Eur J Radiol 101:17–2329571792
46. Zawaideh JP Sala E Shaida N Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice Eur Radiol 2020 30 4039 4049 32166495
Zawaideh JP, Sala E, Shaida N et al (2020) Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice. Eur Radiol 30:4039–404932166495
47. Van Hemelrijck M Ji X Helleman J Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium Eur Urol 2019 75 523 531 30385049
Van Hemelrijck M, Ji X, Helleman J et al (2019) Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium. Eur Urol 75:523–53130385049
48. Kinsella N Helleman J Bruinsma S Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices Transl Androl Urol 2018 7 83 97 29594023
Kinsella N, Helleman J, Bruinsma S et al (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83–9729594023
49. Kinsella N Stattin P Cahill D Factors influencing men’s choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review Eur Urol 2018 74 261 280 29598981
Kinsella N, Stattin P, Cahill D et al (2018) Factors influencing men’s choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review. Eur Urol 74:261–28029598981
50. Eldred-Evans D Tam H Sokhi H Padhani AR Winkler M Ahmed HU Rethinking prostate cancer screening: could MRI be an alternative screening test? Nat Rev Urol 2020 17 526 539 32694594
Eldred-Evans D, Tam H, Sokhi H, Padhani AR, Winkler M, Ahmed HU (2020) Rethinking prostate cancer screening: could MRI be an alternative screening test? Nat Rev Urol 17:526–53932694594
51. Ghavimi S Abdi H Waterhouse J Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging Can Urol Assoc J 2018 12 270 275 30139428
Ghavimi S, Abdi H, Waterhouse J et al (2018) Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Can Urol Assoc J 12:270–27530139428
52. Barrett T de Rooij M Giganti F Allen C Barentsz JO Padhani AR Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway Nat Rev Urol 2023 20 9 22 36168056
Barrett T, de Rooij M, Giganti F, Allen C, Barentsz JO, Padhani AR (2023) Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nat Rev Urol 20:9–2236168056
53. Wassberg C Akin O Vargas HA Shukla-Dave A Zhang J Hricak H The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 2012 199 360 366 22826397
Wassberg C, Akin O, Vargas HA, Shukla-Dave A, Zhang J, Hricak H (2012) The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR. Am J Roentgenol 199:360–36622826397
54. Caglic I Sushentsev N Shah N Warren AY Lamb BW Barrett T Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naïve patients Eur J Radiol 2021 141 109804 34062473
Caglic I, Sushentsev N, Shah N, Warren AY, Lamb BW, Barrett T (2021) Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naïve patients. Eur J Radiol 141:10980434062473
55. Junker D Steinkohl F Fritz V Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019 37 691 699 30078170
Junker D, Steinkohl F, Fritz V et al (2019) Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 37:691–69930078170
56. Bao J Zhi R Hou Y Optimized MRI assessment for clinically significant prostate cancer: a STARD-compliant two-center study J Magn Reson Imaging 2021 53 1210 1219 33075177
Bao J, Zhi R, Hou Y et al (2021) Optimized MRI assessment for clinically significant prostate cancer: a STARD-compliant two-center study. J Magn Reson Imaging 53:1210–121933075177
57. Giganti F Pecoraro M Stavrinides V Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study Eur Radiol 2020 30 2082 2090 31844959
Giganti F, Pecoraro M, Stavrinides V et al (2020) Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. Eur Radiol 30:2082–209031844959
58. Lee KL, Kessler DA, Dezonie S, et al (2023). Assessment of deep learning-based reconstruction on T2-weighted and diffusion-weighted prostate MRI image quality. Eur J Radiol 166:111017
59. Giganti F Allen C Emberton M Moore CM Kasivisvanathan V PRECISION study group Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial Eur Urol Oncol 2020 3 615 619 32646850
Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V, PRECISION study group (2020) Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. Eur Urol Oncol 3:615–61932646850
60. Karanasios E Caglic I Zawaideh JP Barrett T Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up Br J Radiol 2022 95 20211372 35179971
Karanasios E, Caglic I, Zawaideh JP, Barrett T (2022) Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up. Br J Radiol 95:2021137235179971
61. Englman C, Maffei D, Allen C, et al (2024) PRECISE Version 2: Updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer. Eur Urol 30:S0302–2838
62. Sushentsev N Rundo L Blyuss O Gnanapragasam VJ Sala E Barrett T MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance Sci Rep 2021 11 12917 34155265
Sushentsev N, Rundo L, Blyuss O, Gnanapragasam VJ, Sala E, Barrett T(2021) MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance Sci Rep 11:1291734155265
63. Sushentsev N, Rundo L, Blyuss O et al (2021) Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance Eur Radiol 32:680–689
64. Sushentsev N, Rundo L, Abrego L et al (2023) Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol 33:3792–3800
65. Roest C Kwee TC Saha A Fütterer JJ Yakar D Huisman H AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study Eur Radiol 2023 33 89 96 35960339
Roest C, Kwee TC, Saha A, Fütterer JJ, Yakar D, Huisman H (2023) AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study. Eur Radiol 33:89–9635960339
66. Rajwa P, Pradere B, Quhal F et al (2021) Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur Urol 80:549–563
67. Sushentsev N Caglic I Rundo L Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. Br J Radiol 2022 95 20210842 34538077
Sushentsev N, Caglic I, Rundo L et al (2022) Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. Br J Radiol 95:2021084234538077
68. Giganti F, Allen C, Stavrinides V et al (2021) Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease? Br J Radiol 95:20210321
